UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Nature communications, 2019-04, Vol.10 (1), p.1653-16, Article 1653

2019

Link zum Volltext

Verfügbarkeit prüfen

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

Annals of medicine (Helsinki), 2022-12, Vol.54 (1), p.1244-1254

2022

Link zum Volltext

Verfügbarkeit prüfen

RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner

Leukemia, 2021-10, Vol.35 (10), p.2983-2988

2021

Link zum Volltext

Verfügbarkeit prüfen

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice

Internal Medicine, 2023/11/15, Vol.62(22), pp.3299-3303

2023

Link zum Volltext

Verfügbarkeit prüfen

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Nature communications, 2019-08, Vol.10 (1), p.3943-1, Article 3943

2019

Link zum Volltext

Verfügbarkeit prüfen

Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome

Clinical and translational medicine, 2023-08, Vol.13 (8), p.e1327-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Micafungin-induced immune hemolysis attacks

International journal of hematology, 2009-03, Vol.89 (2), p.139-141

2009

Link zum Volltext

Verfügbarkeit prüfen

A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia

European journal of haematology, 2021-03, Vol.106 (3), p.327-339

2021

Link zum Volltext

Verfügbarkeit prüfen

Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53

Blood, 2020-11, Vol.136 (Supplement 1), p.34-34

2020

Link zum Volltext

Verfügbarkeit prüfen

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation

European journal of haematology, 2014-06, Vol.92 (6), p.471-477

2014

Link zum Volltext

Verfügbarkeit prüfen

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

Blood, 2018-11, Vol.132 (Supplement 1), p.761-761

2018

Link zum Volltext

Verfügbarkeit prüfen

High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia

European journal of haematology, 2013-09, Vol.91 (3), p.201-208

2013

Link zum Volltext

Verfügbarkeit prüfen

Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia

International journal of oncology, 2011-01, Vol.38 (1), p.25-31

2011

Link zum Volltext

Verfügbarkeit prüfen

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

Medical oncology (Northwood, London, England), 2018-07, Vol.35 (7), p.99-8, Article 99

2018

Link zum Volltext

Verfügbarkeit prüfen

A family harboring a germ-line N-terminal C/EBPα mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPα mutation

Genes chromosomes & cancer, 2010-03, Vol.49 (3), p.237-241

2010

Link zum Volltext

Verfügbarkeit prüfen

Crebbp HAT Domain Mutations Are Frequently Detected in Adult Acute Lymphoblastic Leukemia

Blood, 2012-11, Vol.120 (21), p.1419-1419

2012

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia

Blood, 2012-11, Vol.120 (21), p.2538-2538

2012

Link zum Volltext

Verfügbarkeit prüfen

IDH1and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

Blood, 2013-11, Vol.122 (21), p.4977-4977

2013

Link zum Volltext

Verfügbarkeit prüfen

IDH1 and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

Blood, 2013-11, Vol.122 (21), p.4977-4977

2013

Link zum Volltext

Verfügbarkeit prüfen

IDH 1 and IDH 2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM 1 mutation

European journal of haematology, 2014-06, Vol.92 (6), p.471-477

2014

Link zum Volltext

Verfügbarkeit prüfen

IDH2 Mutations Have An Unfavorable Impact in Elderly Patients with Acute Myeloid Leukemia

Blood, 2011-11, Vol.118 (21), p.2519-2519

2011

Link zum Volltext

Verfügbarkeit prüfen

Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia

Haematologica (Roma), 2010-09, Vol.95 (9), p.e1-e1

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(37)
Mit Volltextzugriff
(35)

Publikationsform

Artikel
(38)
Berichte
(1)

Sprache

Englisch
(36)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Outcomes of adolescents and young adults with chronic-phase chronic myeloid leukaemia treated with tyrosine kinase inhibitors

RUNX1-ETO (RUNX1-RUNX1T1) induces myeloid leukemia in mice in an age-dependent manner

Core-binding factor fusion downregulation of ADAR2 RNA editing contributes to AML leukemogenesis

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice

Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm

Dissecting the cell of origin of aberrant SALL4 expression in myelodysplastic syndrome

Micafungin-induced immune hemolysis attacks

A regulatory element in the 3′‐untranslated region of CEBPA is associated with myeloid/NK/T‐cell leukemia

Oncofetal Protein SALL4 Is Highly Expressed in Myelodysplastic Syndrome Alongside with NAT10 and P53

IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice

Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm

High frequency of IKZF1 genetic alterations in adult patients with B-cell acute lymphoblastic leukemia

Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors

A family harboring a germ-line N-terminal C/EBPα mutation and development of acute myeloid leukemia with an additional somatic C-terminal C/EBPα mutation

Crebbp HAT Domain Mutations Are Frequently Detected in Adult Acute Lymphoblastic Leukemia

Prognostic Impact and Concurrent Genetic Alterations of CEBPA Double Mutations in Adults with Cytogenetically Intermediate-Risk Acute Myeloid Leukemia

IDH1and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

IDH1 and IDH2 Mutations Confer An Adverse Effect In Patients With Acute Myeloid Leukemia Lacking The NPM1 Mutation

IDH 1 and IDH 2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM 1 mutation

IDH2 Mutations Have An Unfavorable Impact in Elderly Patients with Acute Myeloid Leukemia

Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia

Suchergebnisse filtern